CD169-DTR KO <A HREF="https://mus.brc.riken.jp/en/mouse_of_month/dec_2012_mm" target="_blank">Mouse of the Month Dec 2012</A><br><a href="https://mus.brc.riken.jp/ja/wp-content/uploads/pdf/blc/04395_GB.pdf">Genetic Background</a> CD169-DTR KO The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Nat. Biotechnol., 19, 746-750 (2001). J. Clin Invest., 117, 2268-2278 (2007).In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR/DEVELOPER (Masato Tanaka, Ph.D. and Kenji Kohno, Ph.D.) is requested. Human HB-EGF(DTR) cDNA, Phage P1 loxP site, Mouse Siglec1 genomic DNA Homozygote x Homozygote [or Crossing to C57BL/6JJcl] Homozygote x Homozygote [or Crossing to C57BL/6JJcl] Immunology and Inflammation Research true C (3-6 months) 理化学研究所免疫・アレルギー科学総合研究所。R1 ES細胞を用いて作出。C57BL/6背景。 Masato TANAKA Cre/loxP system 田中　正人 CD169 (Siglec1) DTR knock-in mice. HB-EGF is expressed from CD169 locus. Developed by Masato Tanaka, RIKEN Research Center for Allergy and Immunology. R1 ES cells were used. C57BL/6 background. CD169 (Siglec1) 遺伝子プロモーター下流にヒトジフテリア毒素受容体 (DTR) であるHB-EGF遺伝子を挿入したマウス。ジフテリア毒素 (DT) 投与により脾臓辺縁帯およびリンパ洞に局在するマクロファージ (CD169陽性マクロファージ) が消失する。 C（3〜6か月） RBRC04395 <a href='https://brc.riken.jp/mus/pcr04395'>Genotyping protocol -PCR-</a> R1 [(129X1/SvJ x 129S1/Sv)F1-Kitl<+>] 条件を付加する。利用者は事前に寄託者の提供承諾書を得る。<br>研究成果の公表にあたって寄託者の指定する文献を引用する。Nat. Biotechnol., 19, 746-750 (2001). J. Clin Invest., 117, 2268-2278 (2007).<br>研究成果の公表にあたっては、寄託者/開発者（Masato Tanaka, Ph.D.およびKenji Kohno, Ph.D.）へ謝辞の表明を必要とする。 Necessary documents for ordering:<ol><li>Approval form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_6.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_d.docx">English</A>)</li><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> B6;129-Siglec1<tm1(HBEGF)Mtka> B6;129-Siglec1<tm1(HBEGF)Mtka>